STXSNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31

Stereotaxis, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$1.01+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $101.03M
P/E (TTM): –
Dividend yield: –

Fundamental chart

Pick a measure to chart its full history

$32.38MFY2025, -1.8% a year since FY2011

Where these numbers come from

Parsed from the XBRL in Stereotaxis's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Jul 11, 2012
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is STXS.

Revenue growth-5.5% · median 61.6%

Gross margin55.6% · median 87.0%

Operating margin-75.7% · median -58.6%

Net margin-74.2% · median -62.4%

Company	Revenue	Growth
CVRX	$61.19M	+12.0%
SSII	$52.40M	+89.7%
ECOR	$36.97M	+33.5%
OBIO	$31.98M	+986.1%
STXS	$30.07M	-5.5%
FOCL	–	–

Company

Next earnings (est.): Nov 11, 2026, before open
Exchange: NYSE
Industry: Electromedical & Electrotherapeutic Apparatus
Fiscal year ends: December 31
Employees: 131
Held by institutions: 43.0%
Auditor: Ernst & Young LLP
SEC CIK: 1289340

Advertisement
300 × 250